Abstract
The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) (p=0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 1663-1666 |
| Number of pages | 4 |
| Journal | European Journal of Clinical Microbiology and Infectious Diseases |
| Volume | 31 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2012.07 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Quacquarelli Symonds(QS) Subject Topics
- Medicine
Fingerprint
Dive into the research topics of 'The usefulness of arbekacin compared to vancomycin'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver